Although intravenous (i.v.)delivery of αCTLA-4 and αPD-1/PD-L1 may reach targets in the TME, the critical sites for initiating anti-tumor immune responses may be within the lymphatic vessels and LNs [15]. The gene discussed is CD274; the disease is neoplasm.